LIMITED TIME ONLY

GET 50% OFF

For New & Returning
Customers

Claim Your 50% Off
Black Friday

Article clipped from Mesa Tribune

Capitalism, health care don’t mix well eee ree enterprise has been good to America. Adam Smith’s “invisible hand” — whereby the candle maker’s desire to enrich himself happily results in affordable candles for you and me — has provided the nation with an array of competitively priced products. But does the invisible hand work the right kind of magic when it comes to providing health care? There is unsettling evidence that it does not. Health care is not a product like candles. If we buy candles that drip too much, little harm is done. The consumer can quickly switch brands. When we buy shoddy health insurance, the results can be fatal — and one does not really know how good a policy is until disaster strikes. Under the Clinton health plan, state governments would establish regional health alliances to choose among health plans. They may limit the selection to three. The combination of corrupt state officials and insurance companies fighting for a $1 trillion market does not bode well for consumers. Wall Street has bet heavily on private health care managers — insurers that run health maintenance organizations and preferred provider plans. The stock price of United HealthCare (parent of United Health Plans of New England) has more than quadrupled in three years. Another, U.S. HealthCare, has tripled its price in this period. To improve profitability, companies must sign up as many members as they can and spend as little on health care as they can get away with. U.S. HealthCare managed last year to dramatically lower its medical costs relative to premiums while paying its chief executive more than $3 million. These savings did not all come from reducing paperwork. The insurers attract customers by advertising low upfront costs for visits to the doctor. “We as a nation,” the United HealthCare annual report says, “are coming to realize that preventive care is every bit as necessary, and appropriate, as many forms of acute and chronic care.” The problem is, medical care for minor problems tends to be cheap, whereas high-tech treatments for cancer, heart disease and other illnesses are expensive. And the American medical nightmare is being unable to pay for catastrophic illness, not the annual checkup. Insurers will argue, quite rightly, that if U.S. health care costs are to be held in some kind of check, our society must impose spending limits. Patients in the terminal stages of cancer should be denied expensive treatment. Sickly people in their 80s ought not get a heart transplant. Hospitals and doctors must become more efficient. At some point, however, the understandable desire of insurers to make money collides with To improve profitability, health care management companies must sign up as many members as they can and spend as little on health care as they can get away with society’s expectations for high-tech health care. This is especially true when decisions on treatment fall into gray areas. What about an ill 42-year-old man who stands a 55 percent chance of survival if he gets a $200,000 liver transplant? These judgments are hard enough to make without having to take into account whether an insurer is meeting its quarterly earnings projections. Would you like to be petitioning for life-saving chemotherapy while knowing that a “yes” answer will hurt the executives’ stock options? To meet the anxieties of consumers, for-profit insurers leave the impression that in special cases they will consider paying for treatment outside their network. But when a family tries to take the company up on the implied promise, the insurer often erects a wall of frustration. Patients are assigned a customer representative, whose sole job is to keep them away from the employees who make decisions. Consumers may not talk to these mystery people, who are frequently not qualified to assess a complicated case. Requests are turned down with no explanation. Thus, sick people may require lawyers as well as doctors. A Duke University study found that a quarter of all insurers refused to pay for a promising new breast cancer treatment involving bone marrow transplants and high-dose chemotherapy. The same companies turned down some applicants and not others. The study found a strong correlation between the presence of a family lawyer and the granting of the treatment. Any self-respecting enterprise tries to reduce competition by underpricing the others’ products. Managed care companies with deep pockets can prevail in an industry shakeout, even against nonprofit insurers. After the competition is thinned out, they will be free to raise prices. And the insurers most willing to pay for expensive treatment — and who therefore must charge higher premiums — will be the most vulnerable to cutthroat competition. So the rush is on to speed up doctor visits, reduce hospital stays, refuse experimental treatments. The profit motive has given our society a wealth of choice when it comes to ice cream and dashboards. But medicine is different. When it comes to health care decisions, the invisible hand may not be working in our favor.
Newspaper Details

Mesa Tribune

Mesa, Arizona, US

Tue, Mar 22, 1994

Page 7

Full Page
Clipped by
Profile Icon
Wisdom A.

USA 08 Aug 2025

Other Publications Near Mesa, Arizona
Mesa Tribune Mesa Free Press East Valley Tribune